Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Expert Analysis: Insights for International Clinicians on New Data From CROI 2020

Josep M. Llibre, MD, PhD
Laura Waters, FRCP, MD
Released: April 21, 2020
Back Next

References

  1. Overton ET, Richmond GJ, Rizzardini G, et al. Cabotegravir + rilpivirine every 2 months is noninferior to monthly: ATLAS-2M study. Program and abstracts of the 2020 Conference on Retroviruses and Opportunistic Infections; March 8-11, 2020; Boston, Massachusetts. Abstract 34.
  2. Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med. 2020;382:1112-1123.
  3. Orkin C, Arasteh K, Górgolas Hernández-Mora M, et al. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. N Engl J Med. 2020;382:1124-1135.
  4. Llibre JM, Hung CC, Brinson C, et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet. 2018;391:839-849.
  5. Hagins DP, Kumar PN, Saag M, et al. Randomized switch to B/F/TAF in African American adults with HIV. Program and abstracts of the 2020 Conference on Retroviruses and Opportunistic Infections; March 8-11, 2020; Boston, Massachusetts. Abstract 36.
  6. De Miguel Buckley R, Rial Crestelo D, Dominguez-Dominguez, L, et al. Dolutegravir and lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a pilot clinical trial (ART-PRO). Program and abstracts of the 17th European AIDS Conference; November 6-9, 2019; Basel, Switzerland. Abstract PS7/5.
  7. de Miguel R, Rial D, Domínguez-Domínguez L, et al. Long-term DTG-3TC switch efficacy in patients with archived 3TC resistance. Program and abstracts of the 2020 Conference on Retroviruses and Opportunistic Infections; March 8-11, 2020; Boston, Massachusetts. Abstract 485.
  8. Hill A, McCann KM, Pilkington V, et al. Risks of metabolic syndrome, diabetes, and cardiovascular disease in ADVANCE trial. Program and abstracts of the 2020 Conference on Retroviruses and Opportunistic Infections; March 8-11, 2020; Boston, Massachusetts. Abstract 81.
  9. McCann K, Moorhouse M, Sokhela S, et al. The ADVANCE clinical trial: changes from baseline to week 96 in DXA-assessed body composition in TAF/FTC +DTG compared to TDF/FTC+DTG, and TDF/FTC/EFV. Program and abstracts of the 17th European AIDS Conference; November 6-9, 2019; Basel, Switzerland. Abstract PS3/3.
  10. Young J, Weber R, Rickenbach M, et al. Lipid profiles for antiretroviral-naïve patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. Antivir Ther. 2005;10:585-591.
  11. Schafer JJ, Sassa KN, O’Connor JR, et al. Changes in Body Mass Index and Atherosclerotic Disease Risk Score after switching from tenofovir disoproxil fumarate to tenofovir alafenamide. Open Forum Infect Dis. 2019;6:ofz414.
  12. Griesel R, Maartens G, Sokhela S, et al. CYP2B6 genotype and weight-gain differences between dolutegravir and efavirenz. Program and abstracts of the 2020 Conference on Retroviruses and Opportunistic Infections; March 8-11, 2020; Boston, Massachusetts. Abstract 82.
  13. Meng X, Yin K, Wang J, et al. Effect of CYP2B6 gene polymorphisms on efavirenz plasma concentrations in Chinese patients with HIV infection. PLoS One. 2015;10:e0130583.
  14. Li J, Menard V, Benish RL, et al. Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment. Pharmacogenomics. 2012;13:555-570.
  15. Leonard M, Bourgi K, Koethe JR, et al. Pharmacogenetics of weight gain after switch from efavirenz to integrase inhibitors. Program and abstracts of the 2019 Conference on Retroviruses and Opportunistic Infections; March 4-7, 2019; Seattle, Washington. Abstract 472.
  16. Gallego-Escuredo JM, Del Mar Gutierrez M, Diaz-Delfin J, et al. Differential effects of efavirenz and lopinavir/ritonavir on human adipocyte differentiation, gene expression and release of adipokines and pro-inflammatory cytokines. Curr HIV Res. 2010;8:545-553.
  17. Haubrich RH, Riddler SA, DiRienzo AG, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS. 2009;23:1109-1118.
  18. Castagna A, Maggiolo F, Penco G, et al. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis. 2014;210:354-362.
  19. Callander DJ, Stoové M, McManus H, et al. Decreasing community viremia is associated with decreasing HIV incidence in Australia. Program and abstracts of the 2020 Conference on Retroviruses and Opportunistic Infections; March 8-11, 2020; Boston, Massachusetts. Abstract 48.
  20. Wang X, Nwokolo N, Korologou-Linden R, et al. InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtricitabine in London - analysis of pharmacokinetics, safety and outcomes. HIV Med. 2018;19:1-6.
  21. World Health Organization. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. Available at: https://www.who.int/hiv/pub/guidelines/advanced-HIV-disease/en/. Accessed April 10, 2020.
  22. Ross J, Murenzi G, Hoover DR, et al. Association between time to ART and loss to care among newly diagnosed PLWH in Rwanda. Program and abstracts of the 2020 Conference on Retroviruses and Opportunistic Infections; March 8-11, 2020; Boston, Massachusetts. Abstract 1071.
  23. Koenig SP, Dorvil N, Devieux JG, et al. Same-day HIV testing with imitation of antiretroviral therapy versus standard care for person living with HIV: a randomized unblinded trial. PLoS Med. 2017;14:e1002357.
  24. Rosen S, Maskew M, Fox MP, et al. Initiating antiretroviral therapy for HIV at a patient’s first clinic visit: the RapIT randomized controlled trial. PLoS Med. 2016;13:e1002015.
  25. Labhardt ND, Ringera I, Lejone TI, et al. Effect of offering same-day ART vs usual health facility referral during home-based HIV testing on linkage to care and viral suppression among adults with HIV in Lesotho. The CASCADE randomized clinical trial. JAMA. 2018;319:1103-1112.
  26. Pilcher CD, Ospina-Norvell C, Dasgupta A, et al. The effect of same-day observed initiation of antiretroviral therapy on HIV viral load and treatment outcomes in a US public health setting. J Acquir Infect Dis Soc. 2017;74:44-51.
  27. Coffey S, Bacchetti P, Sachdev D, et al. RAPID antiretroviral therapy: high virologic suppression rates with immediate antiretroviral therapy initiation in a vulnerable urban clinic population. AIDS. 2019;33:825-832.
  28. Bacon O, Chin JC, Hsu L, et al. The Rapid ART Program Initiative for HIV Diagnoses (RAPID) in San Francisco. Program and abstracts of the 2018 Conference on Retroviruses and Opportunistic Infections; March 4-7, 2018; Boston, Massachusetts. Abstract 93.
  29. Ford N, Migone C, Calmy A, et al. Benefits and risks of rapid initiation of antiretroviral therapy. AIDS. 2018;32:17-23.
  30. Seekaew P, Amatavete S, Teeratakulpisarn N, et al. Same-day ART in Thailand: the impact of ART initiation periods on treatment outcomes. Program and abstracts of the 2020 Conference on Retroviruses and Opportunistic Infections; March 8-11, 2020; Boston, Massachusetts. Abstract 1072.
  31. European AIDS Clinical Society. EACS guidelines version 10.0. Available at: https://www.eacsociety.org/files/2019_guidelines-10.0_final.pdf. Accessed April 10, 2020.
  32. Baral SD, Poteat T, Strömdahl S, et al. Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13:214-222.
  33. US Department of Health and Human Services. US statistics: fast facts. Available at: https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics. Accessed April 10, 2020.
  34. Sweeney P, DiNenno EA, Flores SA, et al. HIV data to care-using public health data to improve HIV care and prevention. J Acquir Immune Defic Syndr. 2019;82(suppl 1):S1-S5.
  35. Shamasunder S, Lucas C, Shaw S, et al. Collaborative data-to-care model improves HIV care outcomes in PLWH in Philadelphia. Program and abstracts of the 2020 Conference on Retroviruses and Opportunistic Infections; March 8-11, 2020; Boston, Massachusetts. Abstract 46.
  36. ClinicalTrials.gov. Cooperative re-engagement controlled trial (CoRECT) (CoRECT). Available at: https://clinicaltrials.gov/ct2/show/NCT02693145. Accessed April 10, 2020.
  37. Giordano TP. Strategies for linkage to and engagement with care: focus on intervention. Top Antivir Med. 2018;26:62-65.
  38. Rodger AJ, Cambiano V, Bruun T, et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA. 2016;316:171-181.
  39. Rodger A, Cambiano V, Bruun T, et al. Risk of HIV transmission through condomless sex in MSM couples with suppressive ART: the PARTNER2 Study extended results in gay men. Program and abstracts of the 22nd International AIDS Conference; Amsterdam, Netherlands; July 23-27, 2018. Abstract WEAX0104LB.
  40. Castillo-Mancilla JR. Getting it right: practical approaches to adherence with modern ARVS. Program and abstracts of the 2020 Conference on Retroviruses and Opportunistic Infections; March 8-11, 2020; Boston, Massachusetts. Abstract 160.
  41. Watanabe JH, McInnis T, Hirsch JD. Cost of prescription drug-related morbidity and mortality. Ann Pharmacother. 2018;52:829-837.
  42. Castillo-Mancilla JR, Phillips AN, Neaton AD, et al. Association of suboptimal antiretroviral therapy adherence with inflammation in virologically suppressed individuals enrolled in the SMART study. Open Forum Infect Dis. 2017;5:ofx275.
  43. Pasternak AO, de Bruin M, Jurriaans S, et al. Modest nonadherence to antiretroviral therapy promotes residual HIV-1 replication in the absence of virological rebound in plasma. J Infect Dis. 2012;206:1443-1452.
  44. Rothenberger MK, Keele BF, Wietgrefe SW, et al. Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption. Proc Natl Acad Sci U S A. 2015;112:E1126-E1134.
  45. Kebaabetswe PM, Stirratt MJ, McLellan-Lemal E, et al. Factors associated with adherence and concordance between measurement strategies in an HIV daily oral tenofovir/emtricitabine as pre-exposure prophylaxis (prep) clinical trial, Botswana, 2007-2010. AIDS Behav. 2015;19:758-769.
  46. Musinguzi N, Muganzi CD, Boum Y, et al. Comparison of subjective and objective adherence measures for preexposure prophylaxis against HIV infection among serodiscordant couples in East Africa. AIDS. 2016;30:1121-1129.
  47. Blumenthal J, Pasipanodya EC, Jain S, et al. Comparing self-report pre-exposure prophylaxis adherence questions to pharmacologic measures of recent and cumulative pre-exposure prophylaxis exposure. Front Pharmacol. 2019;10:721.
  48. Castillo-Mancilla JR, Haberer JE. Adherence measurements in HIV: new advancements in pharmacologic methods and real-time monitoring. Curr HIV/AIDS Rep. 2018;15:49-59.
  49. Morrow M, MaWhinney S, Coyle RP, et al. Predictive value of tenofovir diphosphate in dried blood spots for future viremia in persons living with HIV. J Infect Dis. 2019;220:635-642.
  50. Gandhi M, Wang G, King R, et al. Development and validation of the first point-of-care assay to objectively monitor adherence to HIV treatment and prevention in real-time in routine settings. AIDS. 2020;34:255-260.
  51. Spinelli MA, Rodrigues W, Wang G, et al. Near-perfect accuracy of a real-time urine tenofovir test compared to lab-based ELISA. Program and abstracts of the 2020 Conference on Retroviruses and Opportunistic Infections; March 8-11, 2020; Boston, Massachusetts. Abstract 91.
  52. Churchyard G, Cardenas V, Chihota V, et al. Effectiveness of 3-HP annually vs once for HIV-positive people: the WHIP3TB trial. Program and abstracts of the 2020 Conference on Retroviruses and Opportunistic Infections; March 8-11, 2020; Boston, Massachusetts. Abstract 143.
  53. ClinicalTrials.gov. Evaluation of the effect of 3HP vs periodic 3HP vs 6H in HIV-positive individuals (WHIP3TB). Available at: https://clinicaltrials.gov/ct2/show/NCT02980016. Accessed April 10, 2020.
  54. Houben RMG, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med. 2016;13:e1002152.
  55. QuantiFERON-TB Gold Plus. Premarket approval. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?start_search=1&sortcolumn=do_desc&PAGENUM=500&pmanumber=P010033. Accessed April 10, 2020.
  56. European Centre for Disease Control and Prevention. Tuberculosis surveillance and monitoring in Europe, 2019. Available at: https://www.ecdc.europa.eu/en/publications-data/tuberculosis-surveillance-and-monitoring-europe-2019. Accessed April 10, 2020.
  57. Matthews G, Bhagani S, van der Valk M, et al. inferiority Of short duration sofosbuvir-velpatasvir for recent HCV (REACT study).  Program and abstracts of the 2020 Conference on Retroviruses and Opportunistic Infections; March 8-11, 2020; Boston, Massachusetts. Abstract 121.
  58. Boerekamps A, De Weggheleire A, van den Berk GE, et al. Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial. Lancet Gastroenterol Hepatol. 2019;4:269-277.
  59. European Medicines Agency. Zepatier : EPAR - product information. Updated March 9, 2020. Available at: https://www.ema.europa.eu/documents/product-information/zepatier-epar-product-information_en.pdf. Accessed April 10, 2020.
  60. European Medicines Agency. Epclusa : EPAR - product information. Updated March 31, 2020. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/epclusa#product-information-section. Accessed April 10, 2020.
  61. Schinzari V, Barnaba V, Piconese S. Chronic hepatitis B virus and hepatitis C virus infections and cancer: synergy between viral and host factors. Clin Microbiol Infect. 2015;21:969-974.
Back Next
Provided by USF Health, in partnership with Clinical Care Options, LLC

USF Health
Office of Continuing Professional Development (OCPD)
124 S. Franklin Street
Tampa, FL 33602

(800) 852-5362
(813) 224-7860
(813) 224-7864 (Fax)
cpdsupport@usf.edu
https://health.usf.edu/cpd

This activity is supported by educational grants from
Gilead Sciences
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue